Home
EYPT
EYPT News

Latest EyePoint Pharmaceuticals Inc. (EYPT) News on December 18, 2024

EyePoint reports inducement grants under NASDAQ listing rule

TipRanks

a day ago

EyePoint reports inducement grants under NASDAQ listing rule

EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

a day ago

EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

2 days ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint doses first patient in second Phase 3 LUCIA clinical trial

TipRanks

13 days ago

EyePoint doses first patient in second Phase 3 LUCIA clinical trial

EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration

GlobeNewswire

14 days ago

EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

a month ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High?

Zacks

a month ago

Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High?

EyePoint price target lowered to $33 from $38 at Baird

TipRanks

a month ago

EyePoint price target lowered to $33 from $38 at Baird

EyePoint Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

a month ago

EyePoint Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates

Zacks

a month ago

EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates

Associated Press Finance

a month ago

EyePoint Pharmaceuticals: Q3 Earnings Snapshot

EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments

GlobeNewswire

a month ago

EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments

With 61% ownership, EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) boasts of strong institutional backing

Simply Wall St.

a month ago

With 61% ownership, EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) boasts of strong institutional backing

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

GlobeNewswire

a month ago

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

GlobeNewswire

2 months ago

EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

MT Newswires

2 months ago

EyePoint Pharmaceuticals Prices $140 Million Public Offering

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering

GlobeNewswire

2 months ago

EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering

EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock?

Zacks

2 months ago

EyePoint Pharmaceuticals (EYPT) Soars 27.6%: Is Further Upside Left in the Stock?

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

GlobeNewswire

2 months ago

EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock

EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss

Benzinga

2 months ago

EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema

GlobeNewswire

2 months ago

EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration

GlobeNewswire

2 months ago

EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration

ANI Pharmaceuticals price target raised to $62 from $60 at Truist

TipRanks

2 months ago

ANI Pharmaceuticals price target raised to $62 from $60 at Truist

MT Newswires

2 months ago

Scotiabank Initiates EyePoint Pharmaceuticals at Sector Outperform With $18 Price Target

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

2 months ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

GlobeNewswire

3 months ago

EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

MT Newswires

4 months ago

Jefferies Initiates EyePoint Pharmaceuticals at Buy

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

GlobeNewswire

4 months ago

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

Argus Research

4 months ago

Daily – Vickers Top Buyers & Sellers for 08/22/2024

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Some Analysts Just Cut Their EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Estimates

Simply Wall St.

4 months ago

Some Analysts Just Cut Their EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Estimates

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported And Analysts Have Been Cutting Their Estimates

Simply Wall St.

4 months ago

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported And Analysts Have Been Cutting Their Estimates

Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 37% Discount?

Simply Wall St.

4 months ago

Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 37% Discount?

EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

GlobeNewswire

4 months ago

EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates

Zacks

4 months ago

EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates

Associated Press Finance

4 months ago

EyePoint Pharmaceuticals: Q2 Earnings Snapshot

EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments

GlobeNewswire

4 months ago

EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Milestone Pharmaceuticals Refreshes Board of Directors

GlobeNewswire

5 months ago

Milestone Pharmaceuticals Refreshes Board of Directors

EyePoint Pharmaceuticals to Highlight DURAVYU™ (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024

GlobeNewswire

6 months ago

EyePoint Pharmaceuticals to Highlight DURAVYU™ (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024

EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024

GlobeNewswire

6 months ago

EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024

Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?

Zacks

6 months ago

Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

GlobeNewswire

6 months ago

EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

GOBankingRates

6 months ago

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

Bumrah delivers as India beat Pakistan in low-scoring thriller

AFP

6 months ago

Bumrah delivers as India beat Pakistan in low-scoring thriller

Italy beat Bosnia in final Euros warm-up

AFP

6 months ago

Italy beat Bosnia in final Euros warm-up

Trump loyalists proud to support 'felon' at Las Vegas rally

AFP

6 months ago

Trump loyalists proud to support 'felon' at Las Vegas rally

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

Business Insider

6 months ago

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

The Best Woody Perfume For Women

Insider Monkey

6 months ago

The Best Woody Perfume For Women

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

Reuters

6 months ago

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

Insider Monkey

6 months ago

Best Date Night Fragrance in 2024

EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire

6 months ago

EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

Insider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT)

GuruFocus.com

6 months ago

Insider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT)

MT Newswires

6 months ago

JPMorgan Adjusts EyePoint Pharmaceuticals Price Target to $32 From $35, Maintains Overweight Rating

Investing in EyePoint Pharmaceuticals (NASDAQ:EYPT) a year ago would have delivered you a 91% gain

Simply Wall St.

7 months ago

Investing in EyePoint Pharmaceuticals (NASDAQ:EYPT) a year ago would have delivered you a 91% gain

Insider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT)

GuruFocus.com

7 months ago

Insider Sale: Director David Guyer Sells Shares of EyePoint Pharmaceuticals Inc (EYPT)

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

7 months ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Pharmaceuticals Q1 2024 Earnings: Revenue Surpasses Estimates Despite Challenges

GuruFocus.com

7 months ago

EyePoint Pharmaceuticals Q1 2024 Earnings: Revenue Surpasses Estimates Despite Challenges

MT Newswires

7 months ago

Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating

Associated Press Finance

7 months ago

EyePoint Pharmaceuticals: Q1 Earnings Snapshot

EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments

GlobeNewswire

7 months ago

EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments

MT Newswires

7 months ago

Chardan Research Adjusts EyePoint Pharmaceuticals' PT to $28 From $39 After Data From PAVIA Study of Duravyu Disappoint; Keeps Buy Rating

Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?

Benzinga

7 months ago

Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?

MT Newswires

7 months ago

EyePoint Pharmaceuticals Shares Fall After Diabetes Drug Fails to Meet Primary Endpoint

EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy

GlobeNewswire

7 months ago

EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

8 months ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

GlobeNewswire

9 months ago

EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

9 months ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Slashed This Year's Revenue Estimates By 22%

Simply Wall St.

9 months ago

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Slashed This Year's Revenue Estimates By 22%

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript

Insider Monkey

9 months ago

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript

EyePoint Pharmaceuticals Full Year 2023 Earnings: Beats Expectations

Simply Wall St.

9 months ago

EyePoint Pharmaceuticals Full Year 2023 Earnings: Beats Expectations

Thomson Reuters StreetEvents

9 months ago

Q4 2023 EyePoint Pharmaceuticals Inc Earnings Call

EyePoint Pharmaceuticals Inc (EYPT) Reports Growth Amidst Strategic Shifts in Q4 and Full-Year 2023

GuruFocus.com

9 months ago

EyePoint Pharmaceuticals Inc (EYPT) Reports Growth Amidst Strategic Shifts in Q4 and Full-Year 2023

Compared to Estimates, EyePoint Pharmaceuticals (EYPT) Q4 Earnings: A Look at Key Metrics

Zacks

9 months ago

Compared to Estimates, EyePoint Pharmaceuticals (EYPT) Q4 Earnings: A Look at Key Metrics

Associated Press Finance

9 months ago

EyePoint Pharmaceuticals: Q4 Earnings Snapshot

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments

GlobeNewswire

9 months ago

EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments

EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer

GlobeNewswire

9 months ago

EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer

Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should Know

Zacks

10 months ago

Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should Know

Here's Why Momentum in EyePoint Pharmaceuticals (EYPT) Should Keep going

Zacks

10 months ago

Here's Why Momentum in EyePoint Pharmaceuticals (EYPT) Should Keep going

EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024

GlobeNewswire

10 months ago

EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

GlobeNewswire

10 months ago

EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

10 months ago

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Are You Looking for a Top Momentum Pick? Why EyePoint Pharmaceuticals (EYPT) is a Great Choice

Zacks

10 months ago

Are You Looking for a Top Momentum Pick? Why EyePoint Pharmaceuticals (EYPT) is a Great Choice

Wall Street Analysts Think EyePoint Pharmaceuticals (EYPT) Could Surge 31.27%: Read This Before Placing a Bet

Zacks

10 months ago

Wall Street Analysts Think EyePoint Pharmaceuticals (EYPT) Could Surge 31.27%: Read This Before Placing a Bet

Here's What Could Help EyePoint Pharmaceuticals (EYPT) Maintain Its Recent Price Strength

Zacks

10 months ago

Here's What Could Help EyePoint Pharmaceuticals (EYPT) Maintain Its Recent Price Strength

EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

GlobeNewswire

10 months ago

EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

Buy on the Dip Amid Fed's Tepid Rate Cut Signal: 5 Top Picks

Zacks

a year ago

Buy on the Dip Amid Fed's Tepid Rate Cut Signal: 5 Top Picks

Michael Austwick Joins Verona Pharma as Non-Executive Director

GlobeNewswire

a year ago

Michael Austwick Joins Verona Pharma as Non-Executive Director

EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

GlobeNewswire

a year ago

EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

EyePoint Pharmaceuticals Inc SVP & Chief Commercial Officer David Jones Sells 26,017 Shares

GuruFocus.com

a year ago

EyePoint Pharmaceuticals Inc SVP & Chief Commercial Officer David Jones Sells 26,017 Shares

Thomson Reuters StreetEvents

a year ago

Q4 2023 Federated Hermes Inc Earnings Call

In Bad News for IPO Market, BrightSpring Closes Below Offering Price

The Wall Street Journal

a year ago

In Bad News for IPO Market, BrightSpring Closes Below Offering Price

Federated Hermes (FHI) Q4 Earnings Top Estimates, Costs Fall

Zacks

a year ago

Federated Hermes (FHI) Q4 Earnings Top Estimates, Costs Fall

Recursion Pharmaceuticals Inc Director Blake Borgeson Sells 20,054 Shares

GuruFocus.com

a year ago

Recursion Pharmaceuticals Inc Director Blake Borgeson Sells 20,054 Shares

EyePoint Pharmaceuticals Inc's Chief Medical Officer Dario Paggiarino Sells 16,386 Shares

GuruFocus.com

a year ago

EyePoint Pharmaceuticals Inc's Chief Medical Officer Dario Paggiarino Sells 16,386 Shares

Federated Hermes (FHI) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks

a year ago

Federated Hermes (FHI) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Will Fortinet (FTNT) Beat Estimates Again in Its Next Earnings Report?

Zacks

a year ago

Will Fortinet (FTNT) Beat Estimates Again in Its Next Earnings Report?

Oil Climbs Above $75 as Winter Shut-Ins Lead to Big Stock Draw

Zacks

a year ago

Oil Climbs Above $75 as Winter Shut-Ins Lead to Big Stock Draw

Share on Social Networks: